Velinotamig for immune blood cell disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new drug called velinotamig for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not improved with standard treatments. The drug aims to help your body stop attacking its own blood cells, which may improve your blood counts and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with ITP or wAIHA that has not responded to or has returned after standard treatments.
- You are able to care for yourself (ECOG score 0-2).
- Your blood counts and organ function meet certain minimum levels (e.g., hemoglobin at least 6.5 g/dL, kidney function within range).
- You do not have active infections like hepatitis B, C, HIV, or tuberculosis.
- You have not had a solid organ transplant or previous treatment with a BCMA-targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.